

# Artur Katz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3262752/publications.pdf>

Version: 2024-02-01

35  
papers

796  
citations

687363

13  
h-index

501196

28  
g-index

36  
all docs

36  
docs citations

36  
times ranked

1374  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overall Survival and Post-Progression Survival in Advanced Breast Cancer: A Review of Recent Randomized Clinical Trials. <i>Journal of Clinical Oncology</i> , 2010, 28, 1958-1962.	1.6	148
2	Primary systemic chemotherapy of invasive lobular carcinoma of the breast. <i>Lancet Oncology</i> , The, 2007, 8, 55-62.	10.7	92
3	Pretreatment CA 19-9 Level as a Prognostic Factor in Patients with Advanced Pancreatic Cancer Treated with Gemcitabine. <i>International Journal of Gastrointestinal Cancer</i> , 2002, 32, 35-42.	0.4	91
4	Lung cancer in Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2018, 44, 55-64.	0.7	71
5	Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. <i>Lung Cancer</i> , 2017, 108, 238-241.	2.0	62
6	The role of histone deacetylase inhibitors in metastatic breast cancer. <i>Breast</i> , 2019, 43, 130-134.	2.2	42
7	Management of anemia in cancer patients. <i>Future Oncology</i> , 2011, 7, 507-517.	2.4	40
8	A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. <i>Journal of Cancer Research and Clinical Oncology</i> , 1995, 121, 128-131.	2.5	32
9	Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 807-814.	7.7	25
10	Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. <i>Npj Precision Oncology</i> , 2021, 5, 5.	5.4	24
11	<i>Strongyloides</i> hyperinfection in two patients with lymphoma, purulent meningitis, and sepsis. <i>Cancer</i> , 1991, 68, 1821-1823.	4.1	23
12	Assessment of quality of life in advanced breast cancer. An overview of randomized phase III trials. <i>Cancer Treatment Reviews</i> , 2012, 38, 554-558.	7.7	23
13	Shoshin beriberi: report of two successfully treated patients with hemodynamic documentation. <i>American Journal of Cardiology</i> , 1984, 53, 1467.	1.6	19
14	Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. <i>Journal of Surgical Oncology</i> , 2017, 115, 647-662.	1.7	13
15	Phase II Trial of Etoposide (V), Adriamycin (A), and Cisplatinum (P) in Patients with Metastatic Gastric Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1991, 14, 357-358.	1.3	12
16	Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series. <i>Lung Cancer</i> , 2020, 139, 9-12.	2.0	12
17	CALGB 9633: An Underpowered Trial With a Methodologically Questionable Conclusion. <i>Journal of Clinical Oncology</i> , 2009, 27, 2300-2301.	1.6	11
18	COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy. <i>Immunotherapy</i> , 2020, 12, 1133-1138.	2.0	10

#	ARTICLE	IF	CITATIONS
19	Identification of the <i>TP53</i> p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. <i>JCO Global Oncology</i> , 2021, 7, 1141-1150.	1.8	7
20	Acquired Pulmonary Arteriovenous Fistula within Metastasis from Choriocarcinoma: A Case Report. <i>Case Reports in Oncology</i> , 2017, 10, 671-675.	0.7	5
21	Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma. <i>Clinical Lung Cancer</i> , 2021, 22, e481-e486.	2.6	5
22	SARS-CoV-2 testing for asymptomatic adult cancer patients before initiating systemic treatments: a systematic review. <i>Ecancermedalscience</i> , 2020, 14, 1100.	1.1	5
23	Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. <i>Drugs in R and D</i> , 2012, 12, 207-216.	2.2	4
24	Bevacizumab-associated osteonecrosis of the femur and tibia. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz040.	0.4	4
25	Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. <i>Translational Oncology</i> , 2022, 19, 101383.	3.7	4
26	Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?. <i>Clinics</i> , 2017, 72, 588-594.	1.5	3
27	Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab. <i>Case Reports in Oncology</i> , 2009, 2, 57-60.	0.7	1
28	Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	1.6	1
29	Creating solutions through design thinking.. <i>Journal of Global Oncology</i> , 2019, 5, 20-20.	0.5	1
30	Unique <i>SLC12A2-ROS1</i> fusion is associated with marked response to crizotinib in lung adenocarcinoma. <i>SAGE Open Medical Case Reports</i> , 2022, 10, 2050313X2211004.	0.3	1
31	Radiotherapy for a breast cancer patient with Schnitzler syndrome: Report of acute toxicity and early follow-up. <i>Reports of Practical Oncology and Radiotherapy</i> , 2017, 22, 463-469.	0.6	0
32	Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2636-2636.	1.6	0
33	Phase III randomized clinical trials global distribution and funding: Trends and disparities.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18563-e18563.	1.6	0
34	Medical record documentation of cancer patients after an integrated engagement plan.. <i>Journal of Clinical Oncology</i> , 2019, 37, 68-68.	1.6	0
35	Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: A GBECAM multicenter retrospective study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e18822-e18822.	1.6	0